Two-thirds of top 20 pharmas have banned ChatGPT—and many in life sci call AI ‘overrated,’ survey finds
As industries around the globe wrestle with where and how often artificial intelligence (AI) should be implemented in their workflows, biopharma, for one, is proceeding with caution. | As industries around the globe wrestle with where and how often artificial intelligence should be implemented in their workflows, biopharma, for one, is proceeding with caution.